NIERSTICHTING NEDERLAND

Their core work

Nierstichting Nederland (the Dutch Kidney Foundation) is a national patient advocacy and research-funding NGO dedicated to kidney disease. In H2020, they functioned as a third-party contributor, providing the clinical and patient-side infrastructure that academic consortia need but rarely house themselves — disease registries, patient cohorts, access to human tissue samples, and routes into Phase I/II clinical studies. Their role bridges bench research and real-world patient outcomes: they ensure that regenerative medicine and dialysis research stays anchored to actual disease burden and patient populations. For consortium builders, they represent a direct line to the Dutch kidney patient community and to structured clinical data that cannot be obtained through purely academic channels.

What they specialise in

How they've shifted over time

Their two projects run almost concurrently (2018 vs 2019 start), so the shift is subtle but clear. The earlier project, RenalToolBox, sits firmly in the laboratory-facing world — stem cells, nanoparticle cell trackers, imaging algorithms, and preclinical models. The later project, IMPROVE-PD, pivots toward the clinic: peritoneal dialysis management, cardiovascular outcomes, disease registries, and Phase I/II trial infrastructure. This trajectory suggests Nierstichting is moving from enabling basic research (by providing patient samples and disease context) toward enabling clinical translation (by providing structured outcomes data and trial-ready patient populations).

They appear to be positioning as a clinical translation partner — moving from supplying biological material for lab research toward supplying structured patient data and registry infrastructure for outcomes-driven and personalised-medicine trials.

How they like to work

Nierstichting participates exclusively as a third party — they have never coordinated an H2020 project and do not appear as a named participant either. This is consistent with their identity as a patient foundation: they contribute access rights, patient data, and clinical networks rather than leading research agendas. Despite a non-leading role, they connected with 33 distinct consortium partners across 12 countries through just two projects, which indicates that MSCA training networks actively sought them out as a real-world anchor. Working with them means gaining credibility with patient communities and access to Dutch clinical infrastructure, in exchange for aligning research goals with tangible patient benefit.

Through two MSCA-ITN projects, Nierstichting has touched 33 unique consortium partners spread across 12 countries — a notably wide reach for an organisation with no coordinator credits and no direct EC funding. Their network is pan-European by nature of the MSCA programme, though their operational base and patient registry assets are Dutch.

What sets them apart

Nierstichting is one of the few national kidney disease foundations in Europe that engages structurally with H2020 research consortia, making them unusual among NGOs. What they offer is not scientific capacity but something harder to find: legitimacy with patient communities, ethically governed access to kidney disease registries, and a credible clinical translation interface that reviewers and funders reward. For a consortium applying to a health or MSCA call that needs to demonstrate patient and public involvement beyond a tick-box — and that needs real Phase I/II trial pathways — Nierstichting is a materially valuable third-party partner, not just an advisory name on a page.

Highlights from their portfolio

• IMPROVE-PD
  A clinical outcomes-focused MSCA training network on peritoneal dialysis cardiovascular risk, where the foundation's disease-registry and human-tissue access bridges early-career researcher training directly to patient-relevant endpoints.
• RenalToolBox
  An unusually technology-diverse project combining nanoparticle cell trackers, near-infrared dyes, multimodal imaging, and mathematical analysis tools — Nierstichting's involvement anchors this engineering-heavy consortium to real kidney disease clinical need.